# **Data Changes for the CCDD SEPTEMBER Release Candidate 2024**

## **Based on the QA Release Generation 2024-09-03**

|  |  |
| --- | --- |
| **Data entered by** | **A.Raghuveer** |
| **Data checked by** | **M.Taylor** |

## **TM File**

### **Deprecation**

**The following TM concept(s) needs to be added back into the TM File with a status of deprecated. [Reason for deprecation].**

|  |  |  |
| --- | --- | --- |
| **tm\_code** | **tm \_formal\_name** | **tm\_status** |
|  | **[NONE]** |  |

### **Code permanence – name changes**

**The following TM concept(s) need to keep its/their existing tm\_code even though their formal name has changed. [Reason for name change].**

|  |  |  |
| --- | --- | --- |
| **tm\_code (to keep)** | **tm \_formal\_name** | **tm\_code in QA Release was** |
|  | **[NONE]** |  |

### **Concept permanence - returns**

**The following TM concept(s) is/are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate with a status of “inactive”, when its/their supporting NTPs and MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.**

|  |  |
| --- | --- |
| **tm\_code** | **tm \_formal\_name** |
| 8002475 | camphor and lidocaine |
| 8001483 | hyprolose |

## **NTP File**

### **Deprecation**

**The following NTP concept(s) needs to be added back into the NTP File with status of deprecated.**

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | **[NONE]** |  |  |

### **Status update – Inactive**

**The following NTP concept(s) are generating as Active but need to be set to inactive to align with their respective MPs.**

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | **[NONE]** |  | **Inactive** |

### **Code permanence – name changes**

**The following NTP concepts need to keep their existing ntp\_code even though their formal name has changed.**

|  |  |  |
| --- | --- | --- |
| **ntp\_code (to keep)** | **ntp \_formal\_name** | **ntp\_code in QA Release was** |
|  | **[NONE]** |  |

### **Concept permanence – returns check**

**The following NTP concepts are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate, when their supporting MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.**

|  |  |
| --- | --- |
| **ntp\_code** | **ntp \_formal\_name** |
| 9014902 | camphor 3 % and lidocaine hydrochloride 5 % cutaneous solution |
| 9013062 | cytarabine 100 mg per 5 mL solution for injection vial |
| 9013065 | cytarabine 500 mg per 25 mL solution for injection vial |
| 9000355 | erythromycin 333 mg gastro-resistant capsule |
| 9003907 | hyprolose 5 mg ophthalmic insert |
| 9002709 | pilocarpine hydrochloride 4 % ophthalmic drops |
| 9013788 | progesterone 200 mg oral capsule |

## **MP File**

### **Deprecation (very rare)**

**No new deprecated concepts.**

### **Deprecation – manual return**

**The following MP concepts need to be added back into the MP File with status of deprecated. The product has been transferred from DPD to LNHPD.**

|  |  |  |  |
| --- | --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_fr\_description** | **mp\_status** |
|  | **[NONE]** |  | **Deprec** |

### **Status update – deprecation**

**The following MP concepts are generating as active but need to be set to deprecated. Some of these products have been assigned a new DIN, others have been discontinued.**

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | **[NONE]** | **Deprec** |

### **Status update – Inactive**

**The following MP concepts are generating as active but need to be set to inactivated. The DIN is still active but these particular presentations have been discontinued.**

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | **[NONE]** | **Inactive** |

### **DPD descriptors**

**The following concept(s) needs to have the DPD descriptor added to the brand name to allow differentiation between duplicate mp\_formal names.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **drug\_**  **code** | **mp\_code** | **mp\_formal\_name** | **DPD descriptor** | **DPD descriptor - FR** |
| 96059 | 2471477 | OZEMPIC (semaglutide 1.34 mg per mL solution for injection 1.5 mL pen) NOVO NORDISK CANADA INC | MULTIDOSE PREFILLED PEN DISPENSES 0.25MG OR 0.5MG DOSE | MULTIDOSE PREFILLED PEN DISPENSES 0.25MG OR 0.5MG DOSE |
| 96058 | 2471469 | OZEMPIC (semaglutide 1.34 mg per mL solution for injection 1.5 mL pen) NOVO NORDISK CANADA INC | MULTIDOSE PREFILLED PEN DISPENSES 1MG DOSE | MULTIDOSE PREFILLED PEN DISPENSES 1MG DOSE |

### **Concept permanence – manual return**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **drug\_code** | **mp\_code** | **mp\_formal\_name** | **mp\_fr\_description** | **CCDD status** |
|  | **[NONE]** |  |  |  |

### **Code permanence – name changes**

**The following MP concept(s) need to keep its/their existing mp\_code even though their formal name has changed. [Reason for name change].**

|  |  |  |
| --- | --- | --- |
| **mp\_code (to keep)** | **mp \_formal\_name** | **mp\_code in QA Release was** |
|  | **[NONE]** |  |

### **Concept permanence – returns check**

**The following MPs need to be added to the Inclusion list to make sure that they (and their associated NTPs/TMs) continue to be present in the release:**

|  |  |  |  |
| --- | --- | --- | --- |
| **drug\_code** | **mp\_code** | **mp\_formal\_name** | **DPD status** |
| 92979 | 2444674 | ATHENA-ONDANSETRON ODT (ondansetron 4 mg orodispersible tablet) ATHENA PHARMACEUTIQUES SAS | Dormant 2024.08.08 |
| 92980 | 2444682 | ATHENA-ONDANSETRON ODT (ondansetron 8 mg orodispersible tablet) ATHENA PHARMACEUTIQUES SAS | Dormant 2024.08.08 |
| 99847 | 2509164 | BENDAMUSTINE HYDROCHLORIDE FOR INJECTION (bendamustine hydrochloride 25 mg per vial powder for solution for injection) JAMP PHARMA CORPORATION | Dormant 2024.07.31 |
| 10707 | 873454 | ERYC DELAYED-RELEASE CAPSULES (erythromycin 333 mg gastro-resistant capsule) PFIZER CANADA ULC | Cancelled post-market Expiry 2024.08.31 |
| 60041 | 2236754 | FLUVOXAMINE-100 (fluvoxamine maleate 100 mg oral tablet) PRO DOC LIMITEE | Cancelled post-market Expiry 2024.08.31 |
| 60040 | 2236753 | FLUVOXAMINE-50 (fluvoxamine maleate 50 mg oral tablet) PRO DOC LIMITEE | Cancelled post-market Expiry 2024.08.31 |
| 2374 | 884 | ISOPTO CARPINE (pilocarpine hydrochloride 4 % ophthalmic drops) NOVARTIS PHARMACEUTICALS CANADA INC | Cancelled post-market Expiry 2024.08.31 |
| 99220 | 2502631 | JAMP CALCIUM POLYSTYRENE SULFONATE (calcium polystyrene sulfonate 999 mg per g powder for oral/rectal suspension) JAMP PHARMA CORPORATION | Dormant 2024.07.31 |
| 96198 | 2472686 | JAMP GRANISETRON (granisetron (granisetron hydrochloride) 1 mg oral tablet) JAMP PHARMA CORPORATION | Dormant 2024.07.31 |
| 99642 | 2507005 | JAMP TRAMADOL (tramadol hydrochloride 50 mg oral tablet) JAMP PHARMA CORPORATION | Dormant 2024.07.31 |
| 87070 | 2385031 | JAMP-ALENDRONATE (alendronic acid (alendronate sodium) 70 mg oral tablet) JAMP PHARMA CORPORATION | Dormant 2024.07.31 |
| 88713 | 2402289 | JAMP-GABAPENTIN TABLETS (gabapentin 600 mg oral tablet) JAMP PHARMA CORPORATION | Dormant 2024.07.31 |
| 88714 | 2402297 | JAMP-GABAPENTIN TABLETS (gabapentin 800 mg oral tablet) JAMP PHARMA CORPORATION | Dormant 2024.07.31 |
| 88784 | 2403005 | JAMP-LEVETIRACETAM (levetiracetam 250 mg oral tablet) JAMP PHARMA CORPORATION | Dormant 2024.07.31 |
| 88785 | 2403021 | JAMP-LEVETIRACETAM (levetiracetam 500 mg oral tablet) JAMP PHARMA CORPORATION | Dormant 2024.07.31 |
| 88786 | 2403048 | JAMP-LEVETIRACETAM (levetiracetam 750 mg oral tablet) JAMP PHARMA CORPORATION | Dormant 2024.07.31 |
| 85385 | 2368889 | JAMP-PAROXETINE (paroxetine (paroxetine hydrochloride hemihydrate) 30 mg oral tablet) JAMP PHARMA CORPORATION | Dormant 2024.07.31 |
| 81618 | 2330458 | JAMP-QUETIAPINE (quetiapine (quetiapine fumarate) 200 mg oral tablet) JAMP PHARMA CORPORATION | Dormant 2024.07.31 |
| 81615 | 2330415 | JAMP-QUETIAPINE (quetiapine (quetiapine fumarate) 25 mg oral tablet) JAMP PHARMA CORPORATION | Dormant 2024.07.31 |
| 81619 | 2330466 | JAMP-QUETIAPINE (quetiapine (quetiapine fumarate) 300 mg oral tablet) JAMP PHARMA CORPORATION | Dormant 2024.07.31 |
| 90905 | 2424347 | JAMP-SOLIFENACIN (solifenacin succinate 10 mg oral tablet) JAMP PHARMA CORPORATION | Dormant 2024.07.31 |
| 90904 | 2424339 | JAMP-SOLIFENACIN (solifenacin succinate 5 mg oral tablet) JAMP PHARMA CORPORATION | Dormant 2024.07.31 |
| 96171 | 2472406 | JAMP-URSODIOL (ursodiol 500 mg oral tablet) JAMP PHARMA CORPORATION | Dormant 2024.07.31 |
| 73543 | 2250624 | LACRISERT (hyprolose 5 mg ophthalmic insert) BAUSCH & LOMB INC | Cancelled post-market Expiry 2020.08.31 |
| 91489 | 2430436 | MEN EXPERT ANTI-DANDRUFF 2 IN 1 (pyrithione zinc 1 % shampoo) L' OREAL CANADA | Cancelled post-market Expiry 2024.08.31 |
| 83596 | 2350750 | NAPROXEN (naproxen 250 mg oral tablet) SANIS HEALTH INC | Cancelled post-market Expiry 2024.08.31 |
| 99335 | 2503913 | ONDANSETRON INJECTION USP (ondansetron (ondansetron hydrochloride dihydrate) 2 mg per mL solution for injection 20 mL vial) MARCAN PHARMACEUTICALS INC | Cancelled post-market Expiry 2024.08.31 |
| 96790 | 2477149 | PMS-ATORVASTATIN (atorvastatin (atorvastatin calcium) 10 mg oral tablet) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 96791 | 2477157 | PMS-ATORVASTATIN (atorvastatin (atorvastatin calcium) 20 mg oral tablet) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 96792 | 2477165 | PMS-ATORVASTATIN (atorvastatin (atorvastatin calcium) 40 mg oral tablet) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 96793 | 2477173 | PMS-ATORVASTATIN (atorvastatin (atorvastatin calcium) 80 mg oral tablet) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 98579 | 2495899 | PMS-CALCITRIOL (calcitriol 0.25 mcg oral capsule) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 98580 | 2495902 | PMS-CALCITRIOL (calcitriol 0.5 mcg oral capsule) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 84067 | 2355442 | PMS-CELECOXIB (celecoxib 100 mg oral capsule) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 84068 | 2355450 | PMS-CELECOXIB (celecoxib 200 mg oral capsule) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 71828 | 2247573 | PMS-CLARITHROMYCIN (clarithromycin 250 mg oral tablet) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 71829 | 2247574 | PMS-CLARITHROMYCIN (clarithromycin 500 mg oral tablet) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 98571 | 2495813 | PMS-CYCLOSPORINE (cyclosporine 100 mg oral capsule) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 98570 | 2495805 | PMS-CYCLOSPORINE (cyclosporine 25 mg oral capsule) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 98572 | 2495821 | PMS-CYCLOSPORINE (cyclosporine 50 mg oral capsule) PHARMASCIENCE INC | Dormant 2024.07.31 |
| NA | 77700779 | PMS-CYTARABINE (cytarabine 100 mg per 5 mL solution for injection vial) PHARMASCIENCE INC | Dormant 2024.07.31 |
| NA | 77700780 | PMS-CYTARABINE (cytarabine 500 mg per 25 mL solution for injection vial) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 66363 | 2242589 | PMS-METFORMIN (metformin hydrochloride 850 mg oral tablet) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 97078 | 2480247 | PMS-PROGESTERONE (progesterone 200 mg oral capsule) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 89119 | 2406497 | PMS-VANCOMYCIN (vancomycin (vancomycin hydrochloride) 125 mg oral capsule) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 89120 | 2406500 | PMS-VANCOMYCIN (vancomycin (vancomycin hydrochloride) 250 mg oral capsule) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 76415 | 2278561 | PMS-VENLAFAXINE XR (venlafaxine (venlafaxine hydrochloride) 150 mg prolonged-release oral capsule) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 76413 | 2278545 | PMS-VENLAFAXINE XR (venlafaxine (venlafaxine hydrochloride) 37.5 mg prolonged-release oral capsule) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 76414 | 2278553 | PMS-VENLAFAXINE XR (venlafaxine (venlafaxine hydrochloride) 75 mg prolonged-release oral capsule) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 97022 | 2479559 | RIVASTIGMINE PATCH 10 (rivastigmine 9.5 mg per 24 hour transdermal patch) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 97023 | 2479567 | RIVASTIGMINE PATCH 15 (rivastigmine 13.3 mg per 24 hour transdermal patch) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 97021 | 2479540 | RIVASTIGMINE PATCH 5 (rivastigmine 4.6 mg per 24 hour transdermal patch) PHARMASCIENCE INC | Dormant 2024.07.31 |
| 37795 | 2207389 | SHAMPOO CONTROL - 2% (pyrithione zinc 2 % shampoo) AG HAIR LTD | Cancelled post-market Expiry 2024.08.31 |
| 99157 | 2501961 | SKIN SOOTHING AID (camphor 3 % and lidocaine hydrochloride 5 % cutaneous solution) CANADIAN COLLEGE OF HOLISTIC HEALTH | Cancelled post-market Expiry 2023.01.06 |
| 96015 | 2471051 | TARO-DIPYRIDAMOLE/ ASA (acetylsalicylic acid 25 mg and dipyridamole 200 mg modified-release oral capsule) TARO PHARMACEUTICALS INC | Cancelled post-market Expiry 2024.08.31 |
| 81139 | 2326043 | TEVA-AMITRIPTYLINE (amitriptyline hydrochloride 10 mg oral tablet) TEVA CANADA LIMITED | Cancelled post-market Expiry 2022.09.30 |
| 81140 | 2326051 | TEVA-AMITRIPTYLINE (amitriptyline hydrochloride 25 mg oral tablet) TEVA CANADA LIMITED | Cancelled post-market Expiry 2022.05.31 |
| 81141 | 2326078 | TEVA-AMITRIPTYLINE (amitriptyline hydrochloride 50 mg oral tablet) TEVA CANADA LIMITED | Cancelled post-market Expiry 2022.06.30 |
| 91053 | 2425882 | ZOPICLONE TABLETS (zopiclone 7.5 mg oral tablet) NORA PHARMA INC | Cancelled post-market Expiry 2024.08.31 |

## **Exclusion List (on GitHub)**

**The following changes have been made to the Exclusion List for the SEPT 2024 Release Candidate. The list as it is on GitHub should be used.**

**Changes that have been made to the Exclusion List are as follows:  
ACTION is either:**

* **STAY on Exclusion List**
* **ADD to Exclusion List**
* **REMOVE from Exclusion List**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **ntp\_code** | **ntp\_formal\_name** | **drug\_code** | **mp\_code** | **mp\_formal\_name** | **ACTION** |
| 63c8f110ed79d2e861bae01cb8891ce7 | cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection | 100489 | 02515490 | VYXEOS (cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection) JAZZ PHARMACEUTICALS IRELAND LIMITED | STAY |
| 9013678 | dextromethorphan hydrobromide 30 mg per 10 mL syrup | 102364 | 02534754 | DRY COUGH RELIEF EXTRA STRENGTH (dextromethorphan hydrobromide 30 mg per 10 mL syrup) CRLS | REMOVE |
| 169283a59bc6c77d8012716c1d343fd2 | denosumab 60 mg per mL solution for injection | 103418 | 02545411 | JUBBONTI (denosumab 60 mg per mL solution for injection) SANDOZ CANADA INCORPORATED | REMOVE |
| 7eb0cdda74bd99c8d75c41257233fdd7 | dextromethorphan hydrobromide 20 mg per 20 mL and guaifenesin 400 mg per 20 mL oral solution | 91765 | 02433257 | MUCINEX MULTI-ACTION WET & DRY COUGH LIQUID (dextromethorphan hydrobromide 20 mg per 20 mL and guaifenesin 400 mg per 20 mL oral solution) RB HEALTH (CANADA) INC. | REMOVE |
| fe26c1a602dff5187dbc9047794e0bed | cetylpyridinium chloride 0.075 % gargle/mouthwash | 103117 | 02542617 | PERIOGARD PROTECT CETYLPYRIDINIUM CHLORIDE MOUTHWASH (cetylpyridinium chloride 0.075 % gargle/mouthwash) COLGATE-PALMOLIVE CANADA INC | REMOVE |
| 0e45f4009f6cfd6105e58138e3cfdba6 | methylphenidate hydrochloride 20 mg NA | 103024 | 2541602 | QUILLIVANT ER CHEWABLE TABLETS (methylphenidate hydrochloride 20 mg NA) KYE PHARMACEUTICALS INC. | REMOVE |
| 81a272275e9521cb7e2a89fd72810703 | methylphenidate hydrochloride 30 mg NA | 103025 | 2541610 | QUILLIVANT ER CHEWABLE TABLETS (methylphenidate hydrochloride 30 mg NA) KYE PHARMACEUTICALS INC. | REMOVE |
| 6e84171aac7b26461c8359d7326b267e | methylphenidate hydrochloride 40 mg NA | 103026 | 2541629 | QUILLIVANT ER CHEWABLE TABLETS (methylphenidate hydrochloride 40 mg NA) KYE PHARMACEUTICALS INC. | REMOVE |
| bb936839bada78f721f72cfd99081f0c | methylphenidate hydrochloride 5 mg per mL NA | 103027 | 2541637 | QUILLIVANT ER ORAL SUSPENSION (methylphenidate hydrochloride 5 mg per mL NA) KYE PHARMACEUTICALS INC. | ADD |